Therapeutic efficacy of lenvatinib in hepatocellular carcinoma patients with portal hypertension.
albumin-bilirubin grade
hepatocellular carcinoma
lenvatinib
portal hypertension
relative dose intensity
Journal
Hepatology research : the official journal of the Japan Society of Hepatology
ISSN: 1386-6346
Titre abrégé: Hepatol Res
Pays: Netherlands
ID NLM: 9711801
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
23
03
2020
revised:
09
06
2020
accepted:
14
06
2020
pubmed:
20
6
2020
medline:
20
6
2020
entrez:
20
6
2020
Statut:
ppublish
Résumé
Preserved liver function may be an important factor affecting therapeutic efficacy in hepatocellular carcinoma patients treated with lenvatinib, but not all patients can be treated while preserving liver function. This study evaluated the therapeutic efficacy of lenvatinib in patients with poor liver function with and without portal hypertension. This prospectively registered multicenter study analyzed 93 patients treated with lenvatinib. Progression-free survival was compared between patients with and without advanced portal hypertension according to baseline liver function. Advanced portal hypertension was defined as having both splenomegaly and any portosystemic collaterals. A total of 37 patients (40.7%) had advanced portal hypertension. Progression-free survival did not differ between patients with and without advanced portal hypertension in the entire cohort (median 7.6 vs. 4.1 months, respectively; P = 0.148), but was significantly longer in patients with advanced portal hypertension than in those without advanced portal hypertension in the albumin-bilirubin grade 2 or 3 group (median 7.6 vs. 2.1 months, respectively; P = 0.016). In a multivariate analysis, the presence of advanced portal hypertension was identified as the only significant predictor associated with prolonged progression-free survival in the albumin-bilirubin grade 2 or 3 group. Advanced portal hypertension was associated with the therapeutic efficacy of lenvatinib in controlling the progression of hepatocellular carcinoma in patients with poor liver function.
Types de publication
Journal Article
Langues
eng
Pagination
1091-1100Informations de copyright
© 2020 The Japan Society of Hepatology.
Références
Kudo M, Finn RS, Qin S et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018; 391: 1163-1173.
Hiraoka A, Kumada T, Atsukawa M et al. Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis. Cancer Med 2019; 8: 3719-3728.
Ueshima K, Nishida N, Hagiwara S et al. Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study. Cancers (Basel) 2019; 11: 952.
Takahashi A, Moriguchi M, Seko Y et al. Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma. Anticancer Res 2019; 39: 5149-5156.
Sasaki R, Fukushima M, Haraguchi M et al. Response to Lenvatinib Is Associated with Optimal Relative Dose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings. Cancers (Basel) 2019; 11: 1769.
Imani F, Motavaf M, Safari S et al. The therapeutic use of analgesics in patients with liver cirrhosis: a literature review and evidence-based recommendations. Hepat Mon 2014; 14: e23539.
Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008; 64: 1147-1161.
Heimbach JK, Kulik LM, Finn RS et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67: 358-380.
Marrero JA, Kulik LM, Sirlin CB et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2018; 68: 723-750.
Kudo M, Matsui O, Izumi N et al. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan. Liver Cancer 2014; 3: 458-468.
Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
Johnson PJ, Berhane S, Kagebayashi C et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015; 33: 550-558.
Hiraoka A, Kumada T, Michitaka K et al. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2016; 31: 1031-1036.
Hiraoka A, Kumada T, Tsuji K et al. Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis. Liver Cancer 2019; 8: 121-129.
Bezerra AS, D'Ippolito G, Faintuch S, Szejnfeld J, Ahmed M. Determination of splenomegaly by CT: is there a place for a single measurement? AJR Am J Roentgenol 2005; 184: 1510-1513.
Curovic Rotbain E, Lund Hansen D, Schaffalitzky de Muckadell O et al. Splenomegaly - Diagnostic validity, work-up, and underlying causes. PLoS ONE 2017; 12: e0186674.
Bandali MF, Mirakhur A, Lee EW et al. Portal hypertension: Imaging of portosystemic collateral pathways and associated image-guided therapy. World J Gastroenterol 2017; 23: 1735-1746.
Ohya K, Kawaoka T, Namba M et al. Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy. Sci Rep 2019; 9: 12101.
Yamashita T, Kudo M, Ikeda K et al. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol 2020; 55: 113-122.
Hatanaka T, Kakizaki S, Nagashima T et al. Analyses of objective response rate, progression-free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: A multicenter retrospective study. Hepatol Res 2020; 50: 382-395.
Eso Y, Nakano S, Mishima M et al. Dose Intensity/Body Surface Area Ratio is a Novel Marker Useful for Predicting Response to Lenvatinib against Hepatocellular Carcinoma. Cancers (Basel) 2019; 12: 49.
Le Couteur DG, Fraser R, Hilmer S et al. The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance. Clin Pharmacokinet 2005; 44: 187-200.
Dubbelman AC, Nijenhuis CM, Jansen RS et al. Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison. Invest New Drugs 2016; 34: 300-318.
Tamai T, Hayato S, Hojo S et al. Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses. J Clin Pharmacol 2017; 57: 1138-1147.
Shumaker R, Aluri J, Fan J, Martinez G, Pentikis H, Ren M. Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration. J Clin Pharmacol 2015; 55: 317-327.
Ikeda M, Okusaka T, Mitsunaga S et al. Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res 2016; 22: 1385-1394.
Horak J, White J, Harris AL et al. The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib. Cancer Chemother Pharmacol 2011; 68: 1485-1495.
Shibata SI, Chung V, Synold TW et al. Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res 2013; 19: 3631-3639.
de Jong J, Skee D, Hellemans P et al. Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment. Leuk Lymphoma 2017; 58: 185-194.
Krens SD, Lassche G, Jansman FGA et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncol 2019; 20: e200-e207.